KR101959064B1 - Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Staphylococcus epidermidis as an Active Ingredients - Google Patents
Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Staphylococcus epidermidis as an Active Ingredients Download PDFInfo
- Publication number
- KR101959064B1 KR101959064B1 KR1020150140589A KR20150140589A KR101959064B1 KR 101959064 B1 KR101959064 B1 KR 101959064B1 KR 1020150140589 A KR1020150140589 A KR 1020150140589A KR 20150140589 A KR20150140589 A KR 20150140589A KR 101959064 B1 KR101959064 B1 KR 101959064B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- present
- staphylococcus epidermidis
- mediated immune
- strain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 241000191963 Staphylococcus epidermidis Species 0.000 title claims abstract description 51
- 239000004480 active ingredient Substances 0.000 title claims abstract description 14
- 208000026278 immune system disease Diseases 0.000 title abstract description 36
- 230000001404 mediated effect Effects 0.000 title abstract description 34
- 239000000284 extract Substances 0.000 title description 5
- 208000026935 allergic disease Diseases 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 210000003289 regulatory T cell Anatomy 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 230000016396 cytokine production Effects 0.000 claims description 5
- 230000031261 interleukin-10 production Effects 0.000 claims description 4
- 230000019734 interleukin-12 production Effects 0.000 claims description 3
- 235000015429 Mirabilis expansa Nutrition 0.000 claims 1
- 244000294411 Mirabilis expansa Species 0.000 claims 1
- 235000013536 miso Nutrition 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 41
- 108090000695 Cytokines Proteins 0.000 abstract description 41
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 19
- 230000007815 allergy Effects 0.000 abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 10
- 108090000174 Interleukin-10 Proteins 0.000 abstract description 10
- 102000003814 Interleukin-10 Human genes 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 8
- 230000003247 decreasing effect Effects 0.000 abstract description 8
- 230000000172 allergic effect Effects 0.000 abstract description 6
- 208000010668 atopic eczema Diseases 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 4
- 102000018358 immunoglobulin Human genes 0.000 abstract description 4
- 230000003308 immunostimulating effect Effects 0.000 abstract description 4
- 230000006698 induction Effects 0.000 abstract description 4
- 230000009610 hypersensitivity Effects 0.000 abstract description 2
- 230000006057 immunotolerant effect Effects 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 description 21
- 235000018291 probiotics Nutrition 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 17
- 210000002865 immune cell Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 210000001165 lymph node Anatomy 0.000 description 12
- -1 tracant Substances 0.000 description 12
- 235000013305 food Nutrition 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000003266 anti-allergic effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 210000000447 Th1 cell Anatomy 0.000 description 5
- 210000004241 Th2 cell Anatomy 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010003645 Atopy Diseases 0.000 description 4
- 102000003816 Interleukin-13 Human genes 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical class NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000029662 T-helper 1 type immune response Effects 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010061557 Allergic otitis media Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010052748 Bacterial allergy Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- C12R1/45—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 스타필로코쿠스 에피더미디스(Staphylococcus epidermidis) 균주를 유효성분으로 포함하는 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다. 본 발명의 스타필로코쿠스 에피더미디스 KF814는 조절 T 세포 유도, 면역 활성 사이토카인(IL-12)에 대한 면역 관용 사이토카인(IL-10; 항염증성 사이토카인)의 비율 조절, 면역글로불린 E(IgE) 생성 감소 및 면역과민반응 시 Th1-관련 사이토카인 또는 Th2-관련 사이토카인의 감소에 의하여 알레르기 및 염증이 효과적으로 제어하는 바 항알레르기성 조성물 및 항염증성 조성물로 사용이 가능한 이점이 있다.The present invention relates to a composition for preventing, ameliorating or treating a Th1-mediated immune disease or a Th2-mediated immune disease comprising Staphylococcus epidermidis as an active ingredient. The Staphylococcus epidermidis KF814 of the present invention is useful for regulating T cell induction, regulation of the ratio of an immuno tolerant cytokine (IL-10; anti-inflammatory cytokine) to the immunostimulatory cytokine (IL-12), immunoglobulin E Allergic and anti-inflammatory compositions that effectively control allergies and inflammation by reducing Th1-related cytokines or Th2-related cytokines in response to decreased IgE production and immune hypersensitivity.
Description
본 발명은 스타필로코쿠스 에피더미디스(Staphylococcus epidermidis) 균주를 유효성분으로 포함하는 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, ameliorating or treating a Th1-mediated immune disease or a Th2-mediated immune disease comprising Staphylococcus epidermidis as an active ingredient.
최근 미국을 중심으로 장내 세균의 균총을 규명하는 메타지놈 프로젝트 진행결과 장내균총의 분포와 알레르기를 포함하는 다양한 면역계 질환과 상관관계가 밝혀지고 있다. 따라서, 장내 세균의 분포와 다양성 그리고 장 면역과 면역계가 밀접히 연관되어 지고 있음이 규명되고 있는 단계이다. Recently, Metagenome project to identify intestinal microflora in the US has been linked to various immune system diseases including distribution of intestinal microflora and allergy. Therefore, the distribution and diversity of intestinal bacteria and intestinal immunity are closely related to each other.
프로바이오틱스 관련 세계 시장 규모는 2013년 기준 약 29조원이며, 7.6%의 성장률을 보이고 있어 2018년에는 43.4조원 규모로 성장할 것으로 예측된다. 아시아 시장은 2013년 기준 3,500억원 규모로 시장 내 50% 이상은 일본 시장이 차지하고 있다. 국내 프로바이오틱스 시장 규모는 2013년 기준 583억원이며, 2018년까지 연평균 성장률 15%를 보여 2018년에는 1,395억원으로 증가할 것이라 예측되고 있다. The world market for probiotics is expected to grow to W43.4trn in 2018 with a growth rate of 7.6% in 2013, about 29 trillion won. The Asian market is worth W350bn in 2013, with the Japanese market accounting for more than 50% of the market. The domestic probiotic market is expected to grow to W139.5bn by 2018, with annual average growth of 15% until 2018, reaching W58.3bn by 2013.
알레르기억제와 같은 면역제어용 프로바이오틱스 발굴 및 평가 기술은 아직 확립되지 않은 상태임으로, 체계적인 인 비트로 또는 인 비보 모방 스크리닝 시스템을 개발하고 그 기술을 잘 활용한다면 경제적인 효용가치도 막대할 것으로 예상된다. The technology for detecting and evaluating immunity control probiotics such as allergy suppression has not yet been established. Therefore, it is expected that if the systematic in-vitro or in-vivo mimic screening system is developed and utilized well, the economic utility value will also be enormous.
근본적 작용기작에 대한 연구는 미비한 상태이며 대부분의 연구가 인 비트로에서 행해지고 있다. 즉, 프로바이오틱스의 섭취는 구강을 통해 이루어짐에도 불구하고 지금까지의 연구는 대부분 세포주를 이용한 인 비트로 실험이 주를 이루었으며 이러한 실험 방법은 사람이 프로바이오틱스의 섭취 시 나타낼 수 있는 기능에 대한 연구를 대체할 수 없는 큰 단점이 있다. 또한, 프로바이오틱스에 노출되는 장내 면역계(GALT)는 다양한 면역세포가 동시에 존재하여 상호작용을 일으켜 프로바이오틱스의 면역작용을 나타내나 인 비트로 실험은 생체 내 환경과는 차이가 많다. 따라서 프로바이오틱스의 경우 인 비보 시스템에서의 연구가 요구되는 실정이다.Studies of fundamental mechanisms are poor, and most of the work is done in vitro . In other words, despite the oral intake of probiotics, most of the previous studies have focused mainly on in vitro experiments using cell lines, and these experimental methods have been replaced by studies on the ability of humans to ingest probiotics There is a big drawback that can not be. In addition, the intestinal immune system (GALT) exposed to probiotics exhibits immune functions of probiotics due to the presence of various immune cells at the same time, and the in vitro experiment is different from the in vivo environment. Therefore, it is necessary to study in the case of probiotics.
현재 해외의 프로바이오틱스에 대한 면역조절 능력의 평가는 다양한 질환 동물모델에 적용되고 있으며, 그 성과 역시 해마다 가파른 속도로 증가하고 있는 단계이다. 1형 당뇨병, 류마티스 관절염, 퇴행성 관절염, 궤양성 대장염과 같은 염증성 질환들의 염증 반응 억제를 타겟팅하는 분야만이 아니라 독감 바이러스나 암과 같은 질병에 대항할 수 있도록 면역 반응을 증대시킬 수 있는 프로바이오틱스의 기능에 대해서도 연구가 활발히 진행 중이다. 이외에도 알레르기, 천식, 아토피와 같은 질병의 예방 및 치료 목적으로도 프로바이오틱스의 역할 및 그 기능이 많은 주목을 받고 있다.Currently, the evaluation of immunity control for overseas probiotics is applied to various disease animal models, and the results are also increasing at a rapid pace every year. The ability of probiotics to increase the immune response to fight against diseases such as influenza virus or cancer, as well as areas that target inflammatory responses to inflammatory diseases such as
대부분의 프로바이오틱스는 유래가 인간의 장 또는 식품이기 때문에 동물모델을 이용한 효능이 입증되면 다른 화학적 약제와 안정성의 입증에 큰 문제가 없다는 장점이 있다. 또한, 최근 들어 면역조절제로서 프로바이오틱스의 질병 치료 효능이 다양한 임상실험을 통해 검증되고 있다. 천식, 궤양성 대장염, 관절염 등의 질병이 많이 시도되어지고 있으며 최근 들어 아토피에 대한 임상시도 및 연구가 가속화 되고 있는 실정이다.Because most probiotics are derived from human intestines or foods, there is an advantage in that there is no major problem in proving the stability of other chemical agents when proven efficacy using animal models. In addition, recently, the therapeutic effect of probiotics as an immunomodulatory agent has been verified through various clinical trials. Asthma, ulcerative colitis, and arthritis. Recently, clinical trials and studies on atopy have been accelerated.
산업화 동향 분석에 따르면 전통적으로 강세인 유럽에서 프로바이오틱스 개발을 주도하고 있으며 미국, 일본 등지에서도 최근에 기능성 프로바이오틱스 개발 및 사업화가 활발히 진행되고 있는 상태이다. 대표적인 상품으로 VSL3#는 캐나다의 VSL Phamaceutical company에 의해서 개발되었으며, 현재 전세계 시장을 대상으로 활발한 판매활동을 벌이고 있으며 최근에 국내시장에도 면역조절 개별인정형으로 판매되고 있다.According to industrialization trend analysis, it is leading the development of probiotics in Europe, which is traditionally strong, and the development and commercialization of functional probiotics is being actively carried out in the US and Japan recently. VSL3 # was developed by the VSL Phamaceutical company in Canada. It is currently active in the global market, and recently it has been marketed as an immunity regulator in the domestic market.
본 명세서 전체에 걸쳐 다수의 논문 및 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 논문 및 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.
본 발명자들은 Th1 또는 Th2 면역 반응에 의해 유발되는 알레르기 및 염증 질환, 질병 또는 상태를 예방 또는 치료하기 위한 프로바이오틱스를 개발하고자 예의 연구 노력하였다. 그 결과, 전통발효식품인 된장으로부터 항알레르기 및 항염증 활성을 갖는 신규한 스타필로코쿠스 에피더미디스(Staphylococcus epidermidis) 균주를 선별하고, 생쥐에서 직접 분리한 면역세포 및 면역과민 모델에 상기 균주를 처리한 경우 조절 T 세포가 유도되고, 면역 활성 사이토카인(IL-12)에 대한 면역 관용 사이토카인(IL-10; 항염증성 사이토카인)의 비율이 조절되며, 면역글로불린 E(IgE)의 생성이 감소하고, Th1-관련 사이토카인 및 Th2-관련 사이토카인이 감소하여 알레르기 및 염증이 효과적으로 제어됨을 확인함으로써 본 발명을 완성하였다.The present inventors have made extensive efforts to develop probiotics for the prevention or treatment of allergy and inflammatory diseases, diseases or conditions induced by Th1 or Th2 immune responses. As a result, a novel Staphylococcus epidermidis strain having antiallergic and anti-inflammatory activity was selected from soybean paste, which is a traditional fermented food, and immune cells and immunosuppressive models directly isolated from mice were used for the above strain (IL-10; anti-inflammatory cytokine) to the immunostimulatory cytokine (IL-12) is regulated and the production of immunoglobulin E (IgE) , And Th1-related cytokine and Th2-related cytokine are decreased and allergy and inflammation are effectively controlled, thereby completing the present invention.
따라서, 본 발명의 목적은 스타필로코쿠스 에피더미디스 균주를 유효성분으로 포함하는 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물을 제공하는 데 있다.Accordingly, an object of the present invention is to provide a composition for preventing, ameliorating or treating a Th1-mediated immune disease or a Th2-mediated immune disease comprising Staphylococcus epidermidis as an active ingredient.
본 발명의 다른 목적은 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료 활성을 갖는 신규한 스타필로코쿠스 에피더미디스 균주를 제공하는데 있다. It is another object of the present invention to provide a novel Staphylococcus epidermidis strain having a preventive, ameliorative or therapeutic activity of a Th1-mediated immune disease or a Th2-mediated immune disease.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
본 발명의 일 양태에 따르면, 본 발명은 스타필로코쿠스 에피더미디스(Staphylococcus epidermidis) 균주를 유효성분으로 포함하는 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물을 제공한다.According to one aspect of the present invention, there is provided a composition for preventing, ameliorating or treating a Th1-mediated immune disease or a Th2-mediated immune disease comprising Staphylococcus epidermidis strain as an active ingredient do.
본 발명자들은 Th1 또는 Th2 면역 반응에 의해 유발되는 알레르기 및 염증 질환, 질병 또는 상태를 예방 또는 치료하기 위한 프로바이오틱스를 개발하고자 예의 연구 노력하였다. 그 결과, 전통발효식품인 된장으로부터 항알레르기 및 항염증 활성을 갖는 신규한 스타필로코쿠스 에피더미디스 균주를 선별하고, 생쥐에서 직접 분리한 면역세포 및 면역과민 모델에 상기 균주를 처리한 경우 조절 T 세포가 유도되고, 면역 활성 사이토카인(IL-12)에 대한 면역 관용 사이토카인(IL-10; 항염증성 사이토카인)의 비율이 조절되며, 면역글로불린 E(IgE)의 생성이 감소하고, Th1-관련 사이토카인 및 Th2-관련 사이토카인이 감소하여 알레르기 및 염증이 효과적으로 제어됨을 확인하였다.The present inventors have made extensive efforts to develop probiotics for the prevention or treatment of allergy and inflammatory diseases, diseases or conditions induced by Th1 or Th2 immune responses. As a result, a novel strain of Staphylococcus epidermidis having antiallergic and anti-inflammatory activity was selected from soybean paste, which is a traditional fermented food, and when immune cell and immune hypothermia models directly isolated from mice were treated, T cells are induced and the ratio of the immunostimulatory cytokine (IL-10; anti-inflammatory cytokine) to the immunologically active cytokine (IL-12) is regulated, the production of immunoglobulin E (IgE) -Related cytokines and Th2-associated cytokines were reduced and allergies and inflammation were effectively controlled.
따라서 본 발명은 스타필로코쿠스 에피더미디스 균주를 유효성분으로 포함하는 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다.Accordingly, the present invention relates to a composition for preventing, ameliorating or treating a Th1-mediated immune disease or a Th2-mediated immune disease comprising Staphylococcus epidermidis as an active ingredient.
본 명세서에서 용어 “유효성분으로 포함하는”이란 하기의 스타필로코쿠스 에피더미디스 균주의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 본 발명의 스타필로코쿠스 에피더미디스 균주는 식품(예컨대, 된장)으로부터 분리한 미생물 균주인바 과량 투여하여도 인체에 부작용이 없으므로 상기 스타필로코쿠스 에피더미디스 균주는 본 발명의 조성물에 포함된 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve the efficacy or activity of the following Staphylococcus epidermidis strain. Since the Staphylococcus epidermidis strain of the present invention is a microorganism strain isolated from a food (for example, soybean paste) and has no adverse effect on the human body even when administered in an excessive amount, the Staphylococcus epidermidis strain is not contained in the composition of the present invention The quantitative upper limit can be selected by a person skilled in the art within a suitable range.
본 발명의 일 구현예에 따르면, 본 발명의 조성물은 조절 T 세포를 유도한다. 상기 조절 T 세포 유도는 하기 실시예에서 입증한 바와 같이 조절 T 세포 전사인자인 Foxp3 발현 증가에 의하여 확인할 수 있다(도 1).According to one embodiment of the invention, the composition of the invention induces regulatory T cells. The regulatory T cell induction can be confirmed by increased Foxp3 expression, a regulatory T cell transcription factor, as demonstrated in the Examples below (Figure 1).
본 발명의 다른 구현예에 따르면, 본 발명의 조성물은 조절 T 세포를 음성 대조군과 비교하여 2-20배, 5-20배, 8-20배, 2-15배, 5-15배, 8-15배, 2-10배, 5-10배, 8-10배 또는 9-10배 유도한다.According to another embodiment of the present invention, the composition of the present invention is administered to a subject in need thereof by administering to the subject a regulatory T cell that is 2-20, 5-20, 8-20, 2-15, 5-15, 8- 15-fold, 2-10 fold, 5-10 fold, 8-10 fold, or 9-10 fold.
본 발명의 일 구현예에 따르면, 본 발명의 조성물은 IL-10 생성을 증가시킨다. IL-10은 대식세포와 모노사이트 및 T-세포 림프구 복제와 염증성 사이토카인 (IL-1, TNF-α, TGF-β, IL-6, IL-8 및 IL-12)의 분비를 억제하는 림프계 세포에 의해 생성되는 항염증성 사이토카인으로서 IL-10이 증가되면 염증반응이 억제된다.According to one embodiment of the invention, the composition of the present invention increases IL-10 production. IL-10 inhibits the secretion of macrophages and monocytes and T-cell lymphocyte replication and the secretion of inflammatory cytokines (IL-1, TNF-α, TGF-β, IL-6, IL-8 and IL-12) An increase in IL-10 as an anti-inflammatory cytokine produced by cells inhibits the inflammatory response.
본 발명의 일 구현예에 따르면, 본 발명의 조성물은 IL-12 생성량에 대한 IL-10 생성량의 비율을 50-200이 되도록 한다. 본 발명의 다른 구현예에 따르면, 본 발명의 조성물은 IL-12 생성량에 대한 IL-10 생성량의 비율을 100-200, 130-200, 150-200, 100-180, 130-180, 150-180, 100-160, 130-160 또는 150-160이 되도록 한다.According to one embodiment of the present invention, the composition of the present invention is such that the ratio of IL-10 production amount to IL-12 production amount is 50-200. According to another embodiment of the present invention, the composition of the present invention has a ratio of IL-10 production amount to IL-12 production amount of 100-200, 130-200, 150-200, 100-180, 130-180, 150-180 , 100-160, 130-160, or 150-160.
본 발명의 일 구현예에 따르면, 본 발명의 조성물은 IgE 생성을 억제시킨다. IgE는 면역 글로불린 E(immunoglobulin E)로 비만세포 또는 혈중의 호염기구 등에 친화성을 가져 이들에 부착된 IgE 항체와 이에 대응하는 항원(알레르겐)이 반응하면 염증반응을 일으키게 된다. 즉, IgE는 알레르기에 의한 아나필락시스 또는 염증반응을 일으키는 항체인바 상기 IgE 생성이 억제되면 알레르기 반응 또는 염증반응이 억제된다.According to one embodiment of the present invention, the composition of the present invention inhibits IgE production. IgE is an immunoglobulin E, which has an affinity for mucous cells or basophils in the blood, and causes an inflammatory reaction when IgE antibodies attached thereto and the corresponding antigens (allergens) react with each other. That is, IgE is an antibody that causes anaphylactic reaction or inflammatory reaction due to allergy. When the above IgE production is inhibited, allergic reaction or inflammatory reaction is suppressed.
본 발명의 다른 구현예에 따르면, 본 발명의 조성물은 IgE 생성을 음성 대조군과 비교하여 10-70%, 10-60%, 10-50%, 10-45%, 20-70%, 20-60%, 20-50%, 20-45%, 30-70%, 30-60%, 30-50%, 30-45% 또는 35-45% 억제시킨다.According to another embodiment of the present invention, the composition of the present invention comprises 10-70%, 10-60%, 10-50%, 10-45%, 20-70%, 20-60 %, 20-50%, 20-45%, 30-70%, 30-60%, 30-50%, 30-45%, or 35-45%.
본 발명의 일 구현예에 따르면, 본 발명의 조성물은 Th1-관련 사이토카인 생성을 억제시킨다. 따라서 본 발명의 조성물은 다양한 Th1-매개 면역 질환, 질병 또는 상태의 예방, 개선 또는 치료에 이용될 수 있다. 본 발명의 다른 구현예에 따르면, 본 발명의 조성물은 IFN-γ 생성을 억제시킨다.According to one embodiment of the present invention, the composition of the present invention inhibits Th1-associated cytokine production. Thus, the compositions of the present invention can be used for the prevention, amelioration or treatment of various Th1-mediated immune diseases, diseases or conditions. According to another embodiment of the present invention, the composition of the present invention inhibits IFN-y production.
본 명세서에서, 용어 "Th1-매개 면역 질환"은 Th1 세포의 생성 및/또는 활성에 의해 생성되는 사이토카인(Th1-관련 사이토카인), 예컨대, IL-1β, IL-2, IL-12, IFN-γ 또는 TNF-α 등이 관여하는 질환을 의미한다.As used herein, the term "Th1-mediated immune disorder" refers to a cytokine (Th1-associated cytokine) produced by the production and / or activity of Th1 cells such as IL-1β, IL-2, IL- -γ or TNF-α.
본 명세서에서 용어 "Th1 세포"는 유전자 발현, 단백질 분비 및 기능적 활성 측면에서 특정되는 헬퍼 T 세포 림포사이트의 서브세트를 의미한다. 예를 들어, Th1 세포는 IL-2 및 IFN-γ를 합성하지만 IL-4, IL-5, IL-10 및 IL-13는 합성하지 않는 사이토카인 발현 패턴을 나타낸다. Th1 세포는 다양한 세포내 병원균에 대한 세포-매개 면역반응, 기관-특이적 자가면역 질환 및 지연성 과민반응에 관여한다. As used herein, the term "Th1 cell" refers to a subset of helper T cell lymphocytes that are specified in terms of gene expression, protein secretion, and functional activity. For example, Th1 cells synthesize IL-2 and IFN-y, but IL-4, IL-5, IL-10 and IL-13 do not synthesize cytokine expression patterns. Th1 cells are involved in cell-mediated immune responses, organ-specific autoimmune diseases and delayed hypersensitivity reactions to a variety of intracellular pathogens.
본 발명의 조성물이 적용되는 Th1-매개 면역 질환은 특별하게 제한되지 않는다. 예컨대, 본 발명의 조성물이 적용되는 Th1-매개 면역 질환은 대장염, 염증성 장질환, 타입 1 당뇨병, 타입 2 당뇨병, 류마티스 관절염, 반응성 관절염(Reactive Arthritis), 골관절염, 건선, 공피증, 골다공증, 아테롬성 동맥경화증, 심근염, 심내막염, 심낭염, 낭성 섬유증, 하시모토 갑상선염, 그레이브스병, 나병, 매독, 라임 질환(Lyme), 보렐리아증(Borreliosis), 신경성-보렐리아증, 결핵, 사르코이드증(Sarcoidosis), 낭창, 원판성 낭창, 동창성 루프스, 루프스 신염, 전신성 홍반성 루프스, 천식, 황반변성, 포도막염, 과민대장 증후군, 크론씨병, 쇼그랜 증후군, 섬유근통, 만성피로 증후군, 만성피로 면역부전 증후군, 근육통성 뇌척수염, 근위축성 측삭경화증, 파킨스병, 다발경화증, 자폐스펙트럼 장애, 주의력결핍 장애 및 주의력 결핍 과잉행동장애를 포함하나, 이에 한정되는 것은 아니다. 본 발명의 일 구현예에 따르면, 이식 거부, 자가면역질환 또는 염증 질환에 적용된다. 본 발명의 다른 구현예에 따르면, 본 발명의 조성물이 적용되는 Th1-매개 면역 질환은 염증 질환이다.Th1-mediated immune diseases to which the composition of the present invention is applied are not particularly limited. For example, a Th1-mediated immune disorder to which the composition of the present invention is applied is selected from the group consisting of colitis, inflammatory bowel disease,
본 발명의 일 구현예에 따르면, 본 발명의 조성물은 Th2-관련 사이토카인 생성을 억제시킨다. 따라서 본 발명의 조성물은 다양한 Th2-매개 면역 질환, 질병 또는 상태의 예방, 개선 또는 치료에 이용될 수 있다. 본 발명의 다른 구현예에 따르면, 본 발명의 조성물은 IL-4 사이토카인 생성을 억제시킨다. IL-4는 비만세포의 탈과립화를 유도하여 염증성 매개물을 방출함으로써 알레르기 반응을 유도하는 IgE의 분비를 촉진시키는 대표적인 Th2-관련 사이토카인이다. 따라서 IL-4의 생성이 억제되는 경우 알레르기 증상이 완화된다. According to one embodiment of the invention, the composition of the present invention inhibits Th2-associated cytokine production. Thus, the compositions of the present invention can be used for the prevention, amelioration or treatment of various Th2-mediated immune diseases, diseases or conditions. According to another embodiment of the present invention, the composition of the present invention inhibits IL-4 cytokine production. IL-4 is a typical Th2-related cytokine that promotes the secretion of IgE, which induces allergic reactions by inducing degranulation of mast cells and releasing inflammatory mediators. Therefore, if the production of IL-4 is inhibited, allergic symptoms are alleviated.
본 명세서에서, 용어 “Th2-매개 면역 질환”은 알레르겐-특이 Th2 세포의 생성 및 활성에 의한 IgE 및 비만세포가 관여하는 질환을 의미한다.As used herein, the term " Th2-mediated immune disease " refers to diseases in which IgE and mast cells are involved by the production and activity of allergen-specific Th2 cells.
본 명세서에서 용어 “Th2 세포”는 유전자 발현, 단백질 분비 및 기능적 활성 측면에서 특정되는 헬퍼 T 세포 림포사이트의 서브세트를 의미한다. 예를 들어, Th2 세포는 IL-4, IL-5 및 IL-13 사이토카인(Th2-관련 사이토카인) 발현 패턴을 나타낸다. Th2 세포는 체액성 면역반응에 관여한다. As used herein, the term " Th2 cell " refers to a subset of helper T cell lymphocytes that are specified in terms of gene expression, protein secretion, and functional activity. For example, Th2 cells exhibit IL-4, IL-5 and IL-13 cytokine (Th2-related cytokine) expression patterns. Th2 cells are involved in the humoral immune response.
본 발명의 조성물이 적용되는 Th2-매개 면역 질환은 특별하게 제한되지 않으며, 본 발명의 일 구현예에 따르면, 상기 Th2-매개 면역 질환은 알레르기 질환이다.The Th2-mediated immune disease to which the composition of the present invention is applied is not particularly limited, and according to one embodiment of the present invention, the Th2-mediated immune disease is an allergic disease.
본 명세서에서, 용어 “알레르기”는 인체의 어떤 물질에 대한 과민증, 즉 외부로부터 들어온 물질에 대한 신체 면역계의 과도한 반응으로 유발되는 다양한 질환, 질병 또는 이상 상태를 의미한다. 본 발명의 조성물에 적용되는 알레르기 질환으로는, 바람직하게는, 제 Ⅰ 형 즉시형 과민반응 및 제 Ⅳ 형 지연형 과민반응이다. 제 Ⅰ 형 즉시형 과민반응은 기관지 천식, 알레르기성 비염, 아토피성 피부염, 알레르기성 결막염, 알레르기성 중이염, 두드러기 및 아나필라틱 쇼크(anaphylatic shock)이고, 제 Ⅳ 형 지연형 과민반응은 접촉성 과민증, 알레르기성 접촉성 피부염, 세균 알레르기, 진균 알레르기, 바이러스 알레르기, 약물 알레르기, 갑상선염 및 알레르기성 뇌염이다. 제 Ⅰ 형 즉시형 과민반응은 2 단계로 나뉘는데 제 1 단계는 알레르겐의 체내 침입에 의하여 IgE 및 IgG1의 분비를 억제하고, IgG2a의 분비를 증가시키는 IL-12 및 IFN-γ를 생산하는 Th1 세포반응과 IL-4, IL-5 및 IL-13 등을 생산하는 Th2 세포반응의 균형이 Th2 쪽으로 기울어지게 되면 Th2의 과도한 면역반응으로 IL-4 및 IL-13 등이 분비되고 그 영향으로 B 세포가 생산한 IgE 특이항체들이 비만세포(mast cell) 및 호염기구(basophil)의 표면에 부착됨으로써 알레르기 발증이 준비된 단계이다. 이를 알레르겐에 감작되었다고 한다. 알레르기 발증의 제 2 단계는 초기반응과 후기반응으로 나뉘며, 초기반응은 알레르겐이 체내에 재침입하여 비만세포를 자극하고 탈과립 반응을 유발하여 이때 방출된, 히스타민, 지질대사물, 사이토카인 등에 의한 혈관확장 등이 일어나는 것이고, 후기반응은 해당 조직에 호중구, 호산구, 대식세포, Th2 세포, 호염기구 등이 침윤하여 활성화됨으로써 염증이 유발되어 아토피피부염, 비염, 천식 등을 일으키는 것이다. 본 발명의 어떠한 구현예에 의하면, 상기 알레르기는 알레르기성 아토피 피부염이다. As used herein, the term " allergy " refers to a variety of diseases, conditions, or abnormal conditions caused by hypersensitivity to certain substances in the body, i.e., excessive response of the body's immune system to substances introduced from the outside. The allergic diseases to be applied to the composition of the present invention are preferably Type I immediate hypersensitivity reaction and Type IV delayed hypersensitivity reaction. Type I immediate hypersensitivity reactions are bronchial asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, allergic otitis media, urticaria and anaphylatic shock, Type IV delayed hypersensitivity is contact hypersensitivity , Allergic contact dermatitis, bacterial allergies, fungal allergies, viral allergies, drug allergies, thyroiditis and allergic encephalitis. The type I immediate-type hypersensitivity reaction is divided into two stages. The first step is to suppress the secretion of IgE and IgG1 by the invasion of the allergen and the Th1 cell reaction to produce IL-12 and IFN-γ which increase secretion of IgG2a And IL-4, IL-5, and IL-13, the IL-4 and IL-13 are secreted by the excessive immune response of Th2, The IgE-specific antibodies produced are attached to the surface of mast cells and basophils, so that allergic inflammation is prepared. It has been sensitized to allergens. The second stage of the allergic manifestation is divided into an initial reaction and a late reaction. The initial reaction is to re-enter the body to stimulate mast cells and induce a degranulation reaction, which causes release of histamine, lipid metabolites, cytokines, And eosinophil, eosinophil, macrophage, Th2 cell, and basophil are infiltrated into the affected tissue to induce inflammation, resulting in atopic dermatitis, rhinitis, asthma, and the like. According to some embodiments of the present invention, the allergy is allergic atopic dermatitis.
본 발명의 일 구현예에 따르면, 본 발명의 균주는 된장으로부터 분리된 균주이다.According to one embodiment of the present invention, the strain of the present invention is a strain isolated from doenjang.
본 발명의 일 구현예에 따르면, 본 발명의 균주는 스타필로코쿠스 에피더미디스 KF814(기탁번호 KCCM11771P) 균주이다.According to one embodiment of the present invention, the strain of the present invention is Staphylococcus epidermidis KF814 (Accession No. KCCM11771P).
본 발명의 조성물은 약제학적 조성물, 식품 조성물, 기능성 식품 조성물, 화장료 조성물 또는 사료 조성물이다.The composition of the present invention is a pharmaceutical composition, a food composition, a functional food composition, a cosmetic composition or a feed composition.
본 발명의 조성물은 약제학적 조성물로 제조될 수 있다.The compositions of the present invention may be prepared with pharmaceutical compositions.
본 발명의 바람직한 구현예에 따르면, 본 발명의 조성물은 (a) 상술한 본 발명의 스타필로코쿠스 에피더미디스 균주의 약제학적 유효량; 및 (b) 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물이다. 본 명세서에서 용어 “약제학적 유효량”은 상술한 스타필로코쿠스 에피더미디스 균주의 효능 또는 활성을 달성하는 데 충분한 양을 의미한다.According to a preferred embodiment of the present invention, the composition of the present invention comprises (a) a pharmaceutically effective amount of the aforementioned Staphylococcus epidermidis strain of the present invention; And (b) a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to achieve efficacy or activity of the Staphylococcus epidermidis strain described above.
본 발명의 조성물이 약제학적 조성물로 제조되는 경우, 본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체를 포함한다. 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.When the composition of the present invention is manufactured from a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구 투여할 수 있으며, 본 발명의 일 구현예에 따르면 경구 투여 방식으로 적용된다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and may be administered orally in accordance with an embodiment of the present invention.
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 본 발명의 약제학적 조성물에 포함된 생리활성물질인 스타필로코쿠스 에피더미디스 KF814 균주의 투여량은 성인 기준으로 0.0001-1000 ㎎/kg 범위 내이다.The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . The dose of Staphylococcus epidermidis strain KF814, which is a physiologically active substance contained in the pharmaceutical composition of the present invention, is within the range of 0.0001-1000 mg / kg on an adult basis.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액, 시럽제 또는 유화액 형태이거나 엑스제, 산제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
본 발명의 조성물은 기능성 식품 조성물 또는 식품 조성물로 제공될 수 있다.The composition of the present invention may be provided as a functional food composition or a food composition.
본 발명의 조성물이 기능성 식품 조성물 또는 식품 조성물로 제조되는 경우, 유효성분으로서 스타필로코쿠스 에피더미디스 KF814 균주 뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제[타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.When the composition of the present invention is produced from a functional food composition or a food composition, it contains not only the Staphylococcus epidermidis strain KF814 as an active ingredient but also components which are ordinarily added in food production, for example, proteins, Carbohydrates, fats, nutrients, flavoring agents and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 균주 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다. For example, when the food composition of the present invention is prepared as a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract and licorice extract may be further added in addition to the strain of the present invention .
본 발명의 조성물은 화장료 조성물로 제조될 수 있다.The composition of the present invention can be prepared with a cosmetic composition.
본 발명의 스타필로코쿠스 에피더미디스 균주를 유효성분 포함하는 항알레르기용 조성물이 화장료 조성물로 제조되는 경우, 유효 성분으로서의 스타필로코쿠스 에피더미디스 균주 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.When the antiallergic composition comprising the active ingredient of the Staphylococcus epidermidis strain of the present invention is prepared from a cosmetic composition, it contains the components commonly used in cosmetic compositions in addition to Staphylococcus epidermidis strain as an active ingredient And include conventional adjuvants such as stabilizers, solubilizers, vitamins, pigments and flavoring agents, and carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component have.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
본 발명의 조성물은 사료 조성물로 제조될 수 있다.The composition of the present invention may be prepared from a feed composition.
본 발명의 스타필로코쿠스 에피더미디스 균주를 유효성분 포함하는 항알레르기용 조성물이 사료 조성물로 제조되는 경우, 스타필로코쿠스 에피더미디스 균주를 그대로, 또는 사료 제조시 통상적으로 첨가되는 첨가제 등을 가하여 제조할 수 있다. 예컨대, 비타민, 아미노산류, 미네랄 등의 각종 양분, 항산화제, 항생물질, 항균제 및 기타의 첨가제이다. 그 형상에는 분체, 과립, 펠릿 또는 현탁액 등이 포함된다.When the antiallergic composition comprising the active ingredient of the Staphylococcus epidermidis strain of the present invention is prepared from the feed composition, the strain of Staphylococcus epidermidis may be used as it is, or an additive usually added in the production of feed . For example, various nutrients such as vitamins, amino acids and minerals, antioxidants, antibiotics, antibacterial agents and other additives. The shape includes powders, granules, pellets or suspensions, and the like.
본 발명의 조성물이 사료 조성물로 제조되는 경우, 육상 또는 수상 동물에 대하여 단독으로 또는 사료에 혼합하여 공급할 수 있다. 본 발명의 사료에는 분말사료, 고형사료, 모이스트 펠릿사료, 드라이 펠릿사료, EP(Extruder Pellet) 사료, 날먹이 등이 포함되며, 이에 한정되는 것은 아니다.When the composition of the present invention is prepared from a feed composition, it may be supplied to the land or aquatic animals singly or in a feed mixture. The feed of the present invention includes, but is not limited to, powdered feed, solid feed, moist pellet feed, dry pellet feed, extruder pellet (EP) feed,
본 발명의 다른 양태에 따르면, 본 발명은 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료 활성을 갖는 스타필로코쿠스 에피더미디스 KF814(기탁번호 KCCM11771P) 균주를 제공한다.According to another aspect of the present invention, the present invention provides Staphylococcus epidermidis KF814 (Accession No. KCCM11771P) strain having a preventive, ameliorative or therapeutic activity of a Th1-mediated immune disease or a Th2-mediated immune disease.
본 발명의 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료 활성을 갖는 균주는 상술한 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물과 대상 질환을 공통으로 하기 때문에, 상기 조성물과의 관계에서 공통된 내용은 본 명세서의 과도한 복잡성을 피하기 위하여, 그 기재를 생략한다.The strain having the preventive, ameliorating or therapeutic activity of the Th1-mediated immune disease or Th2-mediated immune disease of the present invention is useful for the prevention, amelioration or treatment of a Th1-mediated immune disease or a Th2- In order to avoid the excessive complexity of the present specification, the description in common with the composition is omitted because it is common.
본 발명의 특징 및 이점을 요약하면 다음과 같다: The features and advantages of the present invention are summarized as follows:
(a) 본 발명은 스타필로코쿠스 에피더미디스(Staphylococcus epidermidis) 균주를 유효성분으로 포함하는 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물을 제공한다.(a) The present invention provides a composition for preventing, ameliorating or treating a Th1-mediated immune disease or a Th2-mediated immune disease comprising Staphylococcus epidermidis as an active ingredient.
(b) 본 발명은 Th1-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료 활성을 갖는 신규한 스타필로코쿠스 에피더미디스 KF814 균주(기탁번호 KCCM11771P)를 제공한다. (b) The present invention provides a novel strain of Staphylococcus epidermidis KF814 (Accession No. KCCM11771P) having a preventive, ameliorative or therapeutic activity of a Th1-mediated immune disease or a Th2-mediated immune disease.
(c) 본 발명의 스타필로코쿠스 에피더미디스 균주는 조절 T 세포 유도, 면역 활성 사이토카인(IL-12)에 대한 면역 관용 사이토카인(IL-10; 항염증성 사이토카인)의 비율 조절, 면역글로불린 E(IgE) 생성 감소 및 면역과민반응 시 Th1-관련 사이토카인 및 Th2-관련 사이토카인의 감소에 의하여 알레르기 및 염증을 효과적으로 제어하는 바 항알레르기성 조성물 및 항염증성 조성물로 사용이 가능한 이점이 있다.(c) Staphylococcus epidermidis strains of the present invention are useful for regulating T cell induction, controlling the ratio of an immuno tolerant cytokine (IL-10; anti-inflammatory cytokine) to an immunostimulatory cytokine (IL-12) There is an advantage that it can be used as an anti-allergic composition and an anti-inflammatory composition that effectively controls allergy and inflammation by decreasing the production of globulin E (IgE) and reducing the Th1-related cytokine and Th2-related cytokine upon immunosuppression .
도 1은 스타필로코쿠스 에피더미디스 KF814 균주와 면역세포의 공동배양에 따른 Foxp3의 발현 정도를 측정한 결과를 나타낸다.
도 2a는 스타필로코쿠스 에피더미디스 KF814 균주의 경구 투여에 따른 귀두께 변화를 나타낸다. 도 2b는 스타필로코쿠스 에피더미디스 KF814 균주의 경구 투여에 따른 홍반, 각질 발생 완화 결과를 나타낸다.
도 3은 스타필로코쿠스 에피더미디스 KF814 균주의 경구 투여에 따른 병변지역의 증상 및 면역 세포 침투 정도를 나타낸다.
도 4는 스타필로코쿠스 에피더미디스 KF814 균주의 경구 투여에 따른 IgE 생성 억제 활성을 나타낸다.FIG. 1 shows the results of measuring the expression level of Foxp3 according to co-culture of Staphylococcus epidermidis KF814 and immune cells.
FIG. 2A shows glomerular changes following oral administration of Staphylococcus epidermidis strain KF814. FIG. 2B shows the erythema and erythrocyte mitigation results obtained by oral administration of Staphylococcus epidermidis strain KF814.
FIG. 3 shows symptoms of the lesion area and degree of immune cell penetration according to oral administration of Staphylococcus epidermidis strain KF814.
Fig. 4 shows IgE production inhibitory activity by oral administration of Staphylococcus epidermidis strain KF814.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
실시예Example
실시예 1: 균주의 분리 및 동정Example 1: Isolation and Identification of Strain
균주는 PCA 한천 배지(PCA 배지, BD247940, 디프코社, 미국)를 이용하여 전통식으로 제조된 된장((영)안동제비원식품)으로부터 분리하였으며, 16S rDNA 시퀀싱을 통해 상기 분리된 균주를 동정하였다. 동정 결과, 상기 균주의 16s rDNA 염기서열(서열목록 제1서열)은 기존의 스타필로코쿠스 에피더미디스 ATCC14990(T) 균주와 99.76%의 상동성을 보였다. The strains were isolated from soybean paste (Young An and Dongbangwon Food) prepared by traditional methods using PCA agar medium (PCA medium, BD247940, Difco, USA) and the isolated strains were identified by 16S rDNA sequencing. As a result of the identification, the 16s rDNA sequence (the first sequence of the sequence listing) of the above strain showed 99.76% homology with the conventional Staphylococcus epidermidis strain ATCC14990 (T).
본 균주의 배양을 위한 배지 조성은 PCA 배지이며, 배양조건은 pH 7.0 ± 0.2, 온도 37℃ 및 24시간 정치배양이며, 산소요구성은 통성혐기성이고 동결건조보존 또는 세포현탁액 동결을 통해 균주 보존이 가능하다. 이 균주들을 스타필로코쿠스 에피더미디스(Staphylococcus epidermidis) KF814로 명명하고, 국제미생물기탁기관인 한국미생물보존센터(KCCM)에 2015년 9월 18일자로 기탁하였으며, 기탁번호 기탁번호 KCCM11771P를 부여받았다.The culture medium for the cultivation of this strain is PCA medium. The culture conditions are pH 7.0 ± 0.2, temperature of 37 ° C. and 24 hours of incubation. The oxygen requirement of the strain is anaerobic and can be preserved by freeze-drying preservation or cell suspension freezing Do. These strains were named as Staphylococcus epidermidis KF814 and deposited on September 18, 2015 at the Korean Microorganism Conservation Center (KCCM), which is an international microorganism depository institution, and received deposit number KCCM11771P.
실시예 2: 항알레르기 및 항염증 활성 확인Example 2: Identification of anti-allergic and anti-inflammatory activity
실험동물Experimental animal
본 연구를 위해 유전적으로 어떠한 변형도 일어나지 않은 야생형의 생쥐(계통 번호-C57BL/6, 스탁 번호-000664, the Jackson laboratory)를 사용하였다. 또한, Foxp3의 발현 정도를 비교적 쉽게 확인하기 위해 유전적으로 변형된 생쥐(Foxp3-GFP 넉 인 마우스, 계통 이름-B6.Cg-Foxp3 tm2Tch /J, 스탁 번호-006772, the Jackson laboratory)를 이용하였다. 상기 Foxp3-GFP 넉 인 마우스의 경우 야생형의 종을 기반으로 만들어졌기 때문에 전반적인 유전 정보는 동일하나, Foxp3가 발현할 때 형광 신호를 낼 수 있는 분자인 EGFP(enhanced green fluorescence protein)가 함께 발현하여 이러한 형광 신호가 Foxp3 발현 정도를 대변해 주기 때문에 이 생쥐를 통해 감지가 어려운 Foxp3의 발현 정도를 항체의 사용 없이도 비교적 용이하게 확인할 수 있다.For this study, wild-type mice (strain No. -C57BL / 6, STOCK No. -000664, the Jackson laboratory), which had no genetic modification, were used. In addition, genetically modified mice (Foxp3-GFP knockin mouse, strain name-B6.Cg-Foxp3 tm2Tch / J, STACK No. -006772, the Jackson laboratory) were used to comparatively easily detect the expression level of Foxp3. Foxp3-GFP knock-in mice were constructed based on wild-type species, so their overall genetic information is the same, but EGFP (enhanced green fluorescence protein), a molecule capable of generating a fluorescent signal when Foxp3 is expressed, Since the fluorescence signal represents the degree of Foxp3 expression, the degree of expression of Foxp3, which is difficult to detect through this mouse, can be relatively easily detected without the use of antibodies.
면역 세포 분리 및 스타필로코쿠스 에피더미디스 균주와의 공동배양(co-culture)Immune cell isolation and co-culture with Staphylococcus epidermidis strains
생쥐의 장간막 림프절(MLN: mesenteric lymph node)을 적출한 후, 림프절에 존재하는 면역 세포(대부분 림프구)를 단일 세포 부유하여 실험에 이용하였다. 장내에 존재하는 프로바이오틱스는 장 내 면역계에 존재하는 면역 세포들에 의해 인지되기 때문에 프로바이오틱스의 특성을 분석하기 위해 적절한 면역 세포는 장간막 림프절에 존재하는 면역 세포이다. 따라서, 이 림프절에서 분리한 면역 세포로 스타필로코쿠스 에피더미디스 KF814의 특성을 분석하였다.After the mesenteric lymph node (MLN) of the mouse was extracted, the immune cells (mostly lymphocytes) present in the lymph nodes were suspended in a single cell and used for the experiment. Because the probiotics present in the intestine are recognized by immune cells present in the intestinal immune system, appropriate immune cells are immune cells present in the mesenteric lymph nodes to characterize the probiotics. Therefore, the characteristics of Staphylococcus epidermidis KF814 as an immune cell isolated from this lymph node were analyzed.
공동 배양(co-culture) Co-culture
분리한 면역 세포와 스타필로코쿠스 에피더미디스 KF814는 1:10 비율 즉, 면역 세포 3x106과 균주 3x107 cfu를 72시간 동안 37℃ 배양기에서 배양하였다. 이 때 항생제인 젠타마이신(11811-031, 15 μg/mL, GIBCO社)을 함께 처리하여 시험균주의 과잉성장을 방지하였다.Separated immune cells and Staphylococcus epidermidis KF814 were cultured in a 1:10 ratio, that is, 3x10 6 of the immune cells and 3x10 7 cfu of the strain for 72 hours in a 37 ° C incubator. At that time, the antibiotic gentamycin (11811-031, 15 μg / mL, GIBCO) was treated together to prevent the overgrowth of the test strain.
효소면역측정법(Enzyme-linked immunosorbent assay, ELISA)에 의한 공동배양액 내의 사이토카인 측정Measurement of cytokines in co-culture by enzyme-linked immunosorbent assay (ELISA)
ELISA는 효소를 표식자로 하여 항원항체반응을 이용한 항원 또는 항체의 양을 측정하는 방법 중 하나이다. 면역 세포와 균주를 공동 배양 후 상등액에 존재하는 사이토카인의 양을 측정하기 위해 IL-10(Mouse IL-10 ELISA Ready-SET-Go, eBioscience社) 및 IL-12p70(Mouse IL-12p70 ELISA Ready-SET-Go, eBioscience社) ELISA를 실시하였다. 각각의 사이토카인을 감지하는 코팅용 항체를 96웰에 처리한 후, 상층액을 넣고 일정 시간 동안 반응이 진행되도록 놓아둔 후, 각각의 사이토카인을 감지하는 또 다른 검출용 항체를 처리하였다. 이 때 처리하는 검출용 항체는 효소(HRP)와 결합하고 있는데, 이 때 효소의 기질(Tetramethylbenzidine Substrate Solution, eBioscience)을 첨가하여 효소-기질 반응에 의한 결과물로 색의 변화가 일어난다. 이러한 간접적인 방법을 통해 사이토카인의 절대량을 측정할 수 있다.ELISA is a method of measuring the amount of an antigen or an antibody using an antigen-antibody reaction using an enzyme as a marker. (Mouse IL-10 ELISA Ready-SET-Go, eBioscience) and IL-12p70 (Mouse IL-12p70 ELISA Ready- SET-Go, eBioscience) ELISA. The coating antibody for detecting each cytokine was treated in 96 wells, and the supernatant was added thereto. After allowing the reaction to proceed for a predetermined period of time, another detection antibody for detecting each cytokine was treated. At this time, the antibody for detection is bound to the enzyme (HRP), and a color change occurs as a result of an enzyme-substrate reaction by adding an enzyme substrate (Tetramethylbenzidine Substrate Solution, eBioscience). The absolute amount of cytokine can be measured by this indirect method.
IL-10(interleukin 10)은 대표적인 면역관용 사이토카인이며, IL-12(interleukin 12)는 대표적인 면역활성 사이토카인으로 알려져 있으므로 두 사이토카인의 절대적/상대적 양을 파악하여 항알레르기 특성을 갖은 균주를 선별할 수 있다. 이에 본 실험에서는 Foxp3 넉 인 실험용 생쥐의 장간막 림프절 세포를 분리하여 각각의 시험균주와 1:10 비율 혼합한 후 배양하였다. 3일간 배양 후 배양 상등액을 취하여 면역 활성 사이토카인인 IL-12p70과 항염증 사이토카인인 IL-10의 절대량을 ELISA(Enzyme linked immunosorbent assay)를 통해 측정하였으며, 이 두 분자의 양을 상대적으로 수치화하여 비교하였다.IL-10 (interleukin 10) is a representative immune tolerance cytokine. Since IL-12 (interleukin 12) is known as a representative immunologically active cytokine, the absolute / relative amount of two cytokines is determined and a strain having anti- can do. In this experiment, mesenteric lymph node cells of Foxp3 knockout mice were separated and cultured after mixing 1:10 ratio with each test strain. After culturing for 3 days, the culture supernatant was taken and the absolute amount of IL-12p70, an immunologically active cytokine, and IL-10, an anti-inflammatory cytokine, were measured by ELISA (enzyme linked immunosorbent assay) Respectively.
실험 결과, 스타필로코쿠스 에피더미디스 KF814 균주와 공동배양 시 lL-10 및 IL-12p70의 상대적인 비율(lL-10/IL-12p70)이 153.14로 음성대조군 및 양성대조군(HK Kwon, CG Lee, JS So, CS Chae, JS Hwang, A Sahoo, JH Nam, JH Rhee, KC Hwang, SH Im. 2010. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. PANS. 107;5. 2159-2164)에 비해 높게 나타나 스타필로코쿠스 에피더미디스 KF814의 항염증 활성을 확인하였다.The relative ratio (lL-10 / IL-12p70) of lL-10 and IL-12p70 in co-culture with Staphylococcus epidermidis KF814 strain was 153.14 as negative control and positive control (HK Kwon, CG Lee, ... JS So, CS Chae , JS Hwang, A Sahoo, JH Nam, JH Rhee, KC Hwang, SH Im 2010. Generation of regulatory dendritic cells and CD4 + Foxp3 + T cells by probiotics administration suppresses immune disorders PANS 107; 5. 2159-2164), and the anti-inflammatory activity of Staphylococcus epidermidis KF814 was confirmed.
*미검출(not detect), 검출 영역에서 벗어날 정도도 소량이 분비되므로 항염증활성을 기대할 수 없음.* It is not detectable, and anti-inflammatory activity can not be expected because it secretes a small amount to escape from the detection area.
*IRT5: 5개 균주로 게재된 논문과 특허를 고려할 때 항알레르기 활성이 있는 양성대조군으로 활용할 수 있음.* IRT5: Can be used as a positive control with antiallergic activity considering 5 articles and patents published in 5 strains.
유세포 분석기(Flow cytometry)를 통한 Foxp3 발현 측정Measurement of Foxp3 Expression by Flow Cytometry
유세포 분석기는 레이저를 기반으로 하여 세포의 특정 신호를 감지해 내는 기술로, 분석기에 내재되어 있는 전기 장치에 의해 이러한 신호가 감지되며 이를 통해 살아있는 세포의 생체 분자 발현 정도를 확인할 수 있다. 세포의 표면 분자 발현 정도를 비교하기 위해 스타필로코쿠스 에피더미디스 KF814와 공동 배양한 면역 세포들을 이 유세포 분석기(COULTER Epics XL, BECKMAN社)를 통해 Foxp3가 발현할 때 함께 발현하는 GFP 시그널을 측정함으로써 Foxp3의 발현양을 측정ㆍ비교하였다.A flow cytometer is a laser-based technology that detects specific signals of cells. Such signals are detected by an electrical device embedded in the analyzer, and thus the degree of biomolecular expression of living cells can be checked. Immunocytes co-cultured with Staphylococcus epidermidis KF814 were used to measure the expression of GFP signals when Foxp3 was expressed through this flow cytometer (COULTER Epics XL, BECKMAN) in order to compare the degree of surface expression of the cells. The expression levels of Foxp3 were measured and compared.
조절 T 세포(regulatory T cell)는 T세포의 부분 집합 중 하나로 다른 T 세포와 다르게 과도한 면역 반응을 억제하는 역할을 수행한다. 이러한 조절 T 세포가 알레르기 질환을 억제한다는 것이 다양한 연구 결과를 통해 뒷받침되고 있으므로, 시험균주와 장간막 림프절 세포를 공동배양 시, 조절 T 세포의 분포를 늘릴 수 있는 균주가 항 알레르기 효능을 띠는 프로바이오틱스가 될 가능성이 높다.Regulatory T cells are one of a subset of T cells that, unlike other T cells, play a role in suppressing excessive immune responses. Since these regulatory T cells inhibit allergic diseases, it is supported by various studies. Therefore, when the test strain and mesenteric lymph node cells are co-cultured, the strain capable of increasing the distribution of regulatory T cells is a probiotic having antiallergic effect .
Foxp3는 과도한 면역을 억제하는 T 세포의 서브셋(subset)인 조절 T 세포의 전사인자로, Foxp3 발현 정도를 통해 조절 T 세포의 분포를 확인할 수 있으며, Foxp3 넉 인(Knock-in) 실험용 생쥐를 이용하면, 효율적으로 조절 T 세포(regulatory T cell)의 분포를 평가할 수 있다. 따라서, 시험균주들과 조절 T 세포 간의 상호작용을 알아보기 위해 Foxp3 넉 인 실험용 생쥐의 장간막 림프절 세포를 분리하여 각각의 시험균주와 1:10 비율 혼합한 후 3일간 공동 배양을 진행하였다. 3일 후, 시험균주와 공동 배양한 세포를 걷어 낸 후, Foxp3와 함께 발현하는 GFP의 발현 정도를 유세포 분석기를 통해 확인하였다.Foxp3 is a transcription factor of regulatory T cells, a subset of T cells that inhibit excessive immunity. The Foxp3 expression level can be used to determine the distribution of regulatory T cells. Foxp3 knock-in mice are used , It is possible to evaluate the distribution of regulatory T cells efficiently. Therefore, mesenteric lymph node cells of Foxp3 knock-in mice were separated and tested for 1: 10 ratio with each test strain and then co-cultured for 3 days. After 3 days, the cell co-cultured with the test strain was removed and the expression level of GFP expressed with Foxp3 was confirmed by flow cytometry.
실험 결과, MLN 세포에 스타필로코쿠스 에피더미디스 KF814 균주를 처리 시 Foxp3의 발현량(14.30%)이 대조군에서의 발현량(1.48%)에 비하여 약 9.66배 증가하여 이를 통해 스타필로코쿠스 에피더미디스 KF814 균주가 조절 T 세포 유도 활성이 있어 알레르기 질환을 억제할 수 있음을 확인하였다(도 1).As a result, the expression level of Foxp3 (14.30%) was increased to about 9.66 times that of the control (1.48%) in the treatment of Staphylococcus epidermidis strain KF814 in MLN cells, It was confirmed that the dummy disc KF814 strain has a regulatory T cell inducing activity and can inhibit allergic diseases (Fig. 1).
실시예 3: 항아토피 활성Example 3: Anti-atopic activity
아토피 유도Induction of atopy
스타필로코쿠스 에피더미디스 KF814를 5×108 CFU/일로 주 5회 이상 8주간 경구투여를 진행하였다. 최초 경구투여 3주 후, 마우스의 귀를 외과용 테이프(surgical tape)를 이용하여 벗긴 후 1.0% DNCB(2,4-디나이트로클로로벤젠, 2,4-dinitrochlorobenzene)와 집먼지 진드기 20 μL (10 mg/mL)를 도포하였다. 일주일 후 1% DNCB 및 20 μL(10 mg/mL)의 진드기를 주 1회씩 번갈아 처리하는 방법으로 5주 반복하여 아토피 피부염을 유발시켰다. Staphylococcus epidermidis KF814 was orally administered at 5 × 10 8 CFU / day for 5 weeks or more for 8 weeks. Three weeks after the first oral administration, the ear of the mouse was peeled off with a surgical tape, and 20 μL (10 μL) of 1.0% DNCB (2,4-dinitrochlorobenzene) and house dust mite mg / mL). One week later, 1% DNCB and 20 μL (10 mg / mL) mites were alternately treated once a week for 5 weeks to induce atopic dermatitis.
귀 두께 및 조직학적 변화Ear thickness and histological changes
실험기간 동안 마우스의 귀 두께 변화와 홍반, 부종 및 각질 발생 정도를 측정하였다. 그 결과, PBS 투여군인 샴(음성 대조군)과는 달리, 스타필로코쿠스 에피더미디스 KF814 균주 경구 투여시 귀 두께가 감소하였으며(도 2a), 귀부분에 홍반, 부종 및 각질이 심하게 일어난 음성 대조군과는 달리, 스타필로코쿠스 에피더미디스 KF814 균주 경구 투여 시 상기 증상이 경미하게 나타났다(도 2b).During the experimental period, changes in ear thickness, erythema, edema and keratinization of the mice were measured. As a result, unlike the PBS-administered group Sham (negative control), the ear thickness decreased when oral administration of Staphylococcus epidermidis KF814 strain (Fig. 2a), and a negative control group with severe erythema, edema and keratinization , The above symptoms were slightly observed upon oral administration of Staphylococcus epidermidis strain KF814 (Fig. 2B).
또한 염증 부위인 귀조직의 조직학적 분석 결과, 스타필로코쿠스 에피더미디스 KF814 투여군이 샴 군에 비해 상피세포(epithelial cell) 두께가 감소하였으며, 염증 세포의 침윤도 억제되었음을 확인하였다(도 3). In addition, histological analysis of the ear tissue, which is an inflammatory site, showed that epithelial cell thickness was decreased and infiltration of inflammatory cells was suppressed compared with that of Sham group (Fig. 3).
이러한 귀 두께 감소와 염증 침윤억제 정도는 양성대조군인 IRT5투여와 유사한 수준으로 스타필로코쿠스 에피더미디스 KF814 균주의 아토피 피부염 억제 활성이 매우 높음을 확인할 수 있다.This decrease in ear thickness and degree of inhibition of inflammation infiltration are similar to the administration of IRT5, which is a positive control, and the activity of inhibiting atopic dermatitis of Staphylococcus epidermidis KF814 strain is very high.
사이토카인 변화Cytokine change
세포학적 분석을 위하여 마우스의 림프절[드레이닝 림프절: 표면 림프절, 액와부 림프절, 기관지 림프절)]에서 드레이닝 림프구를 분리한 후, 항원인 진드기로 세포를 자극시킨 다음 발현되는 사이토카인을 e-Bioscience사의 사이토카인 정량 키트를 이용하여 ELISA 방법을 통해 확인하였다.For cytologic analysis, draining lymphocytes were isolated from mouse lymph nodes (draining lymph node: surface lymph node, axillary lymph node, bronchial lymph node)], and then the cells were stimulated with an antigen, mite, and the expressed cytokine was analyzed by e-Bioscience ELISA method using a cytokine quantitative kit.
그 결과, 하기 표 2에서 볼 수 있는 바와 같이 스타필로코쿠스 에피더미디스 KF814을 각각 지속적으로 투여한 실험군에서는 아토피 피부염 발병 및 악화를 촉진하는 염증성 사이토카인인 IFN-γ의 양이 감소하는 양상을 보였으며, Th2-관련 사이토카인인 IL-4의 분비량도 감소하여 스타필로코쿠스 에피더미디스 KF814가 아토피 피부염 억제 활성이 있음을 확인하였다.As a result, as shown in Table 2 below, the amount of IFN-y, an inflammatory cytokine that promotes atopic dermatitis development and deterioration, decreased in the experiment group in which Staphylococcus epidermidis KF814 was continuously administered , And secretion of IL-4, a Th2-related cytokine, was also decreased, confirming that Staphylococcus epidermidis KF814 inhibited atopic dermatitis.
혈청 IgE 변화Changes in serum IgE
실험종료 후 마우스 안와정맥을 통해 채혈한 후, 3500 rpm에서 10분간 원심분리하여 혈청을 분리하였다. 분리한 혈청 내 IgE 함량은 BD사의 마우스 IgE 정량 키트를 사용하여 측정하였다.After the end of the experiment, blood was drawn through the mouse orbit, and the serum was separated by centrifugation at 3500 rpm for 10 minutes. The IgE content in the separated serum was measured using a mouse IgE quantitative kit from BD.
그 결과, 하기 도 4에서 볼 수 있는 바와 같이 스타필로코쿠스 에피더미디스 KF814 균주 투여시 알레르기 증상과 밀접한 관련이 있는 IgE가 샴군 대비 39% 감소하였다(PBS: 51.11 μg/mL, IRT: 37.78 μg/mL, 814: 31.20 μg/mL).As a result, IgE, which is closely related to the allergic symptoms, was decreased by 39% compared to the Sham group when Staphylococcus epidermidis strain KF814 was administered (PBS: 51.11 μg / mL, IRT: 37.78 μg / mL, 814: 31.20 [mu] g / mL).
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.
<110> KOREA FOOD RESEARCH INSTITUTE <120> Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Staphylococcus epidermidis as an Active Ingredients <130> PN150427 <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 1374 <212> DNA <213> 16S rDNA of Staphylococcus epidermidis KF814 <400> 1 gtagcatgct gatctacgat tactagcgat tccagcttca tatagtcgag ttgcagacta 60 caatccgaac tgagaacaac tttatgggat ttgcttgacc tcgcggtttc gctgcccttt 120 gtattgtcca ttgtagcacg tgtgtagccc aaatcataag gggcatgatg atttgacgtc 180 atccccacct tcctccggtt tgtcaccggc agtcaactta gagtgcccaa cttaatgatg 240 gcaactaagc ttaagggttg cgctcgttgc gggacttaac ccaacatctc acgacacgag 300 ctgacgacaa ccatgcacca cctgtcactc tgtcccccga aggggaaaac tctatctcta 360 gaggggtcag aggatgtcaa gatttggtaa ggttcttcgc gttgcttcga attaaaccac 420 atgctccacc gcttgtgcgg gtccccgtca attcctttga gtttcaacct tgcggtcgta 480 ctccccaggc ggagtgctta atgcgttagc tgcagcacta aggggcggaa accccctaac 540 acttagcact catcgtttac ggcgtggact accagggtat ctaatcctgt ttgatcccca 600 cgctttcgca catcagcgtc agttacagac cagaaagtcg ccttcgccac tggtgttcct 660 ccatatctct gcgcatttca ccgctacaca tggaattcca ctttcctctt ctgcactcaa 720 gttttccagt ttccaatgac cctccacggt tgagccgtgg gctttcacat cagacttaaa 780 aaaccgccta cgcgcgcttt acgcccaata attccggata acgcttgcca cctacgtatt 840 accgcggctg ctggcacgta gttagccgtg gctttctgat taggtaccgt caagacgtgc 900 atagttactt acacatttgt tcttccctaa taacagagtt ttacgatccg aagaccttca 960 tcactcacgc ggcgttgctc cgtcaggctt tcgcccattg cggaagattc cctactgctg 1020 cctcccgtag gagtctggac cgtgtctcag ttccagtgtg gccgatcacc ctctcaggtc 1080 ggctacgcat cgttgccttg gtaagccgtt accttaccaa ctagctaatg cggcgcggat 1140 ccatctataa gtgacagcaa aaccgtcttt cactattgaa ccatgcggtt caatatatta 1200 tccggtatta gctccggttt cccgaagtta tcccagtctt ataggtaggt tatccacgtg 1260 ttactcaccc gtccgccgct aacgtcagag gagcaagctc ctcgtctgtt cgctcgactt 1320 gcatgtatta ggcacgccgc cagcgttcat cctgagccat gatcaaactc tgtc 1374 <110> KOREA FOOD RESEARCH INSTITUTE <120> Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Staphylococcus epidermidis as an Active Ingredients <130> PN150427 <160> 1 <170> Kopatentin 2.0 <210> 1 <211> 1374 <212> DNA <213> 16S rDNA of Staphylococcus epidermidis KF814 <400> 1 gtagcatgct gatctacgat tactagcgat tccagcttca tatagtcgag ttgcagacta 60 caatccgaac tgagaacaac tttatgggat ttgcttgacc tcgcggtttc gctgcccttt 120 gtattgtcca ttgtagcacg tgtgtagccc aaatcataag gggcatgatg atttgacgtc 180 atccccacct tcctccggtt tgtcaccggc agtcaactta gagtgcccaa cttaatgatg 240 gcaactaagc ttaagggttg cgctcgttgc gggacttaac ccaacatctc acgacacgag 300 ctgacgacaa ccatgcacca cctgtcactc tgtcccccga aggggaaaac tctatctcta 360 gaggggtcag aggatgtcaa gatttggtaa ggttcttcgc gttgcttcga attaaaccac 420 atgctccacc gcttgtgcgg gtccccgtca attcctttga gtttcaacct tgcggtcgta 480 ctccccaggc ggagtgctta atgcgttagc tgcagcacta aggggcggaa accccctaac 540 acttagcact catcgtttac ggcgtggact accagggtat ctaatcctgt ttgatcccca 600 cgctttcgca catcagcgtc agttacagac cagaaagtcg ccttcgccac tggtgttcct 660 ccatatctct gcgcatttca ccgctacaca tggaattcca ctttcctctt ctgcactcaa 720 gttttccagt ttccaatgac cctccacggt tgagccgtgg gctttcacat cagacttaaa 780 aaaccgccta cgcgcgcttt acgcccaata attccggata acgcttgcca cctacgtatt 840 accgcggctg ctggcacgta gttagccgtg gctttctgat taggtaccgt caagacgtgc 900 atagttactt acacatttgt tcttccctaa taacagagtt ttacgatccg aagaccttca 960 tcactcacgc ggcgttgctc cgtcaggctt tcgcccattg cggaagattc cctactgctg 1020 cctcccgtag gagtctggac cgtgtctcag ttccagtgtg gccgatcacc ctctcaggtc 1080 ggctacgcat cgttgccttg gtaagccgtt accttaccaa ctagctaatg cggcgcggat 1140 ccatctataa gtgacagcaa aaccgtcttt cactattgaa ccatgcggtt caatatatta 1200 tccggtatta gctccggttt cccgaagtta tcccagtctt ataggtaggt tatccacgtg 1260 ttactcaccc gtccgccgct aacgtcagag gagcaagctc ctcgtctgtt cgctcgactt 1320 gcatgtatta ggcacgccgc cagcgttcat cctgagccat gatcaaactc tgtc 1374
Claims (12)
A composition for preventing, ameliorating or treating an allergic disease comprising Staphylococcus epidermidis strain KF814 of Accession No. KCCM11771P as an active ingredient.
2. The composition of claim 1, wherein said composition induces regulatory T cells.
The composition of claim 1, wherein the composition is such that the ratio of IL-10 production to IL-12 production is 50-200.
2. The composition of claim 1, wherein the composition inhibits IgE production.
2. The composition of claim 1, wherein the composition inhibits Th1-associated cytokine production.
2. The composition of claim 1, wherein said composition inhibits Th2-associated cytokine production.
The composition according to claim 1, wherein the strain is a strain isolated from soybean miso.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150140589A KR101959064B1 (en) | 2015-10-06 | 2015-10-06 | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Staphylococcus epidermidis as an Active Ingredients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150140589A KR101959064B1 (en) | 2015-10-06 | 2015-10-06 | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Staphylococcus epidermidis as an Active Ingredients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170041338A KR20170041338A (en) | 2017-04-17 |
| KR101959064B1 true KR101959064B1 (en) | 2019-03-18 |
Family
ID=58703210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150140589A KR101959064B1 (en) | 2015-10-06 | 2015-10-06 | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Staphylococcus epidermidis as an Active Ingredients |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101959064B1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111763630A (en) * | 2019-03-27 | 2020-10-13 | 深圳微健康基因科技有限公司 | Staphylococcus epidermidis and application thereof |
| KR102186420B1 (en) * | 2019-10-17 | 2020-12-03 | 고려대학교 산학협력단 | Composition for preventing, improving or treating of allergic diseases comprising Staphylococcus succinus 14BME20 as an active ingredient |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150106357A (en) * | 2014-03-10 | 2015-09-21 | 동아에스티 주식회사 | Pharmaceutical composition for the treatment or prevention of stroke and systemic embolism |
-
2015
- 2015-10-06 KR KR1020150140589A patent/KR101959064B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| Frontiers in Immunology 2015. 07., volume 6, Article 353* |
| 한국공개특허공보 제2015-0106357호 (2015. 9. 25.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170041338A (en) | 2017-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101644595B1 (en) | A composition for preventing, improving or treating a Th1-mediated immune disease or a Th2-mediated immune disease comprising Lactobacillus paracasei as an active ingredient | |
| JP5718917B2 (en) | Novel Lactobacillus plantarum and composition containing the same | |
| TWI324068B (en) | Antiallergic composition | |
| US11141444B2 (en) | Lactobacillus crispatus KBL693 strain and use thereof | |
| KR101724126B1 (en) | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease, Th17-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Lactococcus lactis as an Active Ingredients | |
| WO2011111734A1 (en) | Lactic acid bacterium-containing preparation | |
| CN101171019A (en) | immune function modulator | |
| KR101644594B1 (en) | A composition for preventing, ameliorating or treating a Th1-mediated immune disease or a Th2-mediated immune disease comprising Lactobacillus casei as an active ingredient | |
| KR101635997B1 (en) | A composition for preventing, ameliorating or treating a Th1-mediated disease or a Th2-mediated immune disease comprising Pediococcus acidilactici as an active ingredient | |
| KR101890428B1 (en) | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Pediococcus pentosaceus as an Active Ingredients | |
| KR101406168B1 (en) | Novel lactobacillus plantarum and compositions comprising the same | |
| KR101959064B1 (en) | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Staphylococcus epidermidis as an Active Ingredients | |
| JP2009057346A (en) | Composition for regulating immune balance | |
| KR101761506B1 (en) | Composition for Preventing, Improving, or Treating of Th1-mediated Immune Disease, Th17-mediated Immune Disease, or Th2-mediated Immune Disease Comprising Extracts from Lactobacillus pentosus as an Active Ingredients | |
| KR101644593B1 (en) | Anti-Allergic Compositions Comprising Bacillus amyloliquefaciens 26N As Active Ingredients | |
| KR20170041337A (en) | Composition for Preventing, Improving or Treating of Th1-mediated Immune Disease or Th2-mediated Immune Disease Comprising Extracts from Bacillus amyloliquefaciens subsp. plantarum as an Active Ingredients | |
| KR20140048911A (en) | Novel lactobacillus plantarum and compositions comprising the same | |
| KR101414120B1 (en) | Anti-Allergic Compositions Comprising Bacillus amyloliquefaciens or Substances of Fermented Soy Bean Using The Strain | |
| KR101414123B1 (en) | Anti-Allergic Compositions Comprising Bacillus aryabhattai or Substances of Fermented Soy Bean Using The Species | |
| KR101947276B1 (en) | Composition for immune enhanvement comprising sargassum coreanum enzymatic extract | |
| RU2791561C2 (en) | Lactobacillus crispatus kbl693 strain and its application | |
| KR102143615B1 (en) | Novel Kazachstania turicensis CAU Y1706, and compositions using the same | |
| KR101821118B1 (en) | Composition for Preventing or Treating Allergic Disease Comprising Gambogic Acid | |
| KR101414119B1 (en) | Anti-Allergic Compositions Comprising Bacillus methylotrophicus or Substances of Fermented Soy Bean Using The Species | |
| KR101414122B1 (en) | Anti-Allergic Compositions Comprising Bacillus subtilis subsp. inaquosorum or Substances of Fermented Soy Bean Using The Subspecies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20151006 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20161006 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20151006 Comment text: Patent Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180813 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190220 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20190308 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20190311 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20190311 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20220110 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20221205 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20231226 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20241223 Start annual number: 7 End annual number: 7 |